A 35-year-old man from Mumbai presents with a 5-year history of obsessions about harming his young daughter through careless acts (e.g., leaving a knife within her reach, driving recklessly near her). He has no history of violent behavior and is deeply distressed by these thoughts. To manage his anxiety, he repeatedly checks that doors are locked, windows are closed, and his daughter is safe—sometimes 20–30 times per day. His wife reports he has become withdrawn and his work performance has declined. He has been on fluoxetine 60 mg daily for 3 months with minimal improvement. What is the most appropriate next step in management?

Explanation

## Clinical Assessment **Key Point:** This patient has severe, treatment-resistant OCD (inadequate response to adequate SSRI dose and duration). The obsessions are harm-related (aggressive intrusions), and compulsions are safety-checking behaviors. Diagnosis is clear; the challenge is optimizing treatment. ## Definition of Treatment Resistance **High-Yield:** Treatment-resistant OCD is defined as: - Inadequate response (< 25% reduction in Yale-Brown Obsessive-Compulsive Scale [Y-BOCS] score) after - ≥ 8–12 weeks of SSRI at therapeutic dose (fluoxetine 60 mg is adequate) - With documented compliance This patient meets criteria: 3 months on fluoxetine 60 mg with minimal improvement. ## Management Algorithm for Treatment-Resistant OCD ```mermaid flowchart TD A[OCD diagnosed]:::outcome --> B[SSRI at therapeutic dose<br/>for 8-12 weeks]:::action B --> C{Adequate response?}:::decision C -->|Yes| D[Continue SSRI<br/>+ CBT/ERP]:::action C -->|No| E[Treatment-resistant OCD]:::outcome E --> F{Optimize current SSRI?}:::decision F -->|Increase dose or<br/>extend duration| G[Reassess at 12 weeks]:::action F -->|Switch to<br/>clomipramine| H[Clomipramine trial<br/>100-150 mg/day]:::action G --> I{Response?}:::decision H --> I I -->|Yes| J[Continue + CBT/ERP]:::action I -->|No| K[Add augmentation agent]:::action K --> L[Antipsychotic:<br/>risperidone, aripiprazole]:::action L --> M{Response?}:::decision M -->|Partial| N[Consider intensive CBT/ERP]:::action M -->|No| O[Consider specialist referral<br/>or advanced options]:::action ``` **Clinical Pearl:** Switching from one SSRI to another or to clomipramine is reasonable before augmentation, as response rates vary between agents (30–50% switch response). ## Options for Treatment-Resistant OCD | Strategy | Evidence | Timeline | Notes | | --- | --- | --- | --- | | **Switch to clomipramine** | Strong | 8–12 weeks at therapeutic dose | 30–50% of SSRI non-responders respond | | **Augment with antipsychotic** | Strong | 4–6 weeks (risperidone, aripiprazole) | Add to current SSRI; low-dose risperidone 2–6 mg/day | | **Intensive CBT/ERP** | Strong | 16–20 sessions over 8–12 weeks | Gold standard; should accompany pharmacotherapy | | **Increase SSRI dose** | Weak | 4–6 weeks | Fluoxetine 60 mg is already adequate; higher doses show minimal additional benefit | | **Augment with other agents** | Weak | Variable | Augmentation with clonazepam, lamotrigine, or N-acetylcysteine has limited evidence | ## Most Appropriate Next Step **High-Yield:** The best next step is **augmentation with a low-dose antipsychotic (risperidone 2–4 mg/day or aripiprazole 10–15 mg/day) added to the current fluoxetine**, with concurrent referral for intensive CBT/ERP. **Rationale:** 1. Fluoxetine 60 mg is already at therapeutic dose; further dose escalation offers minimal benefit 2. Switching to clomipramine is a reasonable alternative, but augmentation has faster onset and strong evidence 3. Risperidone or aripiprazole augmentation has FDA support and robust evidence in treatment-resistant OCD (response rate ~60%) 4. **CBT/ERP is essential:** Medication alone is insufficient; intensive behavioral therapy with exposure and response prevention should be initiated concurrently **Warning:** Do NOT simply increase fluoxetine beyond 60 mg or add benzodiazepines as first-line augmentation. Antipsychotics have the strongest evidence. ## Expected Outcomes - **With augmentation + CBT/ERP:** 50–70% achieve significant improvement (≥35% Y-BOCS reduction) - **Timeline:** 4–6 weeks for antipsychotic effect; 8–12 weeks for full CBT/ERP benefit **Clinical Pearl:** Harm-related obsessions (like this patient's fear of harming his daughter) often respond well to ERP, as the feared outcome (actual harm) is extremely unlikely, making habituation achievable. [cite:Harrison 21e Ch 385; American Psychiatric Association Practice Guidelines for OCD]